131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
About this item
Full title
Author / Creator
Publisher
United States: Soc Nuclear Med
Journal title
Language
English
Formats
Publication information
Publisher
United States: Soc Nuclear Med
Subjects
More information
Scope and Contents
Contents
(131)I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer and leukemia. There are still some uncertainties concerning parameters that may influence the effective half-life of (131)I and the absorbed doses by extrathyroidal organs.
Whole-body retention of radioiodine was measured in 254 patients, and rep...
Alternative Titles
Full title
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_18703593
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_18703593
Other Identifiers
ISSN
0161-5505
E-ISSN
1535-5667
DOI
10.2967/jnumed.108.052464
